Before Ozempic, Wegovy, Mounjaro and Zepbound, there was Lotte Bjerre Knudsen.
In the 1990s, the young scientist at the Danish drug company Novo Nordisk was trying to unlock the key to a new technology for treating Type 2 diabetes. To her bosses, Lotte’s project, which focused on a hormone called GLP-1, looked like a distraction.
But as Lotte fought to save her diabetes project from the chopping block, she couldn’t have imagined how much of an impact her breakthrough would have. Her work would pave the way for a hit drug called Ozempic. And it would unleash a new class of blockbuster drugs, pitting two companies in a race to become the world’s first trillion-dollar pharmaceutical company by market cap.
Listen to Part 1 of “Trillion Dollar Shot” now.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Hope, Unity (and Some Nerves) at the DNC
Outcry at Bank of America Over Dangerous Workloads
The Inside Story of Starbucks’s CEO Drama
At the DNC, Democrats Are Divided Over Gaza
The Economy: Trump vs. Harris
Is the Trump Campaign Going Off Track?
She Was Google’s First Landlord. And She Changed the Internet.
One Man’s Campaign Against DEI
China Is Finally Doing Something About the Fentanyl Crisis
Boeing's Long Flight Delay – in Space
Will Tracking Cocoa Beans Help Save the Rainforest?
$25 Billion to Zero: Bill Ackman’s Bungled IPO
Judge Rules ‘Google Is a Monopolist’
What the Stock Market Panic Says About the Economy
Who is Filing Thousands of Disability Lawsuits Against Businesses?
'Phony' and 'Weird.' Trump and Harris Size Each Other Up
The Historic U.S.-Russia Prisoner Swap
Alexa is in Millions of Homes and Amazon is Losing Billions
The Paris Olympics’ $1.5 Billion Poop Problem
The Slaves Sending You Scam Texts
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Minute Briefing
WSJ Tech News Briefing
Marketplace Tech